14 completed, 3 terminated, 2 unknown, 1 active not recruiting. 7 Phase 2, 5 Phase 1, 4 Not applicable, 3 Early Phase 1, 3 Phase 3.
Follow Cutaneous Lupus Erythematosus: new trials by email Literature Review of Cutaneous Lupus Erythematosus trials Research Report on Cutaneous Lupus Erythematosus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) Enpatoran, Placebo, Standard of care (SoC) - Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus | Phase 3 | Recruiting | EMD Serono Research & Development Institute, Inc. | 202 | 2026-04-01 | 2026-10-06 |
| Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants.. ACT100 Injection, Placebo for ACT100 - Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus | Phase 1 | Not yet recruiting | Xiamen Amoytop Biotech Co., Ltd. | 48 | 2026-03-06 | 2026-02-13 |
| Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants SOF-SKN 0.25%, SOF-SKN 0.5%, SOF-SKN 1% - Cutaneous Lupus Erythematosus | Early Phase 1 | Completed | Noxopharm Limited | 24 | 2025-07-14 | 2026-09-02 |
| Tapinarof for Cutaneous Lupus Erythematosus Tapinarof - Cutaneous Lupus Erythematosus | Early Phase 1 | Enrolling by invitation | Northwestern University | 10 | 2025-04-03 | 2026-04-29 |
| A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus Anifrolumab, Placebo - Cutaneous Lupus Erythematosus | Phase 3 | Active not recruiting | AstraZeneca | 339 | 2024-06-29 | 2026-07-29 |
| Deep Phenotyping of Cutaneous Lupus Erythematosus IMIQUIMOD cream 50mg/g - Cutaneous Lupus Erythematosus | Not applicable | Unknown | Centre for Human Drug Research, Netherlands | 40 | 2024-06-01 | 2024-05-13 |
| Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE) Edecesertib, Placebo, Standard of Care - Cutaneous Lupus Erythematosus | Phase 1 | Terminated | Gilead Sciences | 3 | 2021-09-01 | 2024-04-05 |
| Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus SAR443122, Placebo - Cutaneous Lupus Erythematosus | Phase 2 | Completed | Sanofi | 78 | 2021-04-01 | 2025-08-27 |
| Study of M5049 in CLE and SLE Participants M5049, Placebo - Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus | Phase 1 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 25 | 2020-12-16 | 2024-02-21 |
| A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis VIB7734, Placebo - Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus | Phase 1 | Completed | Amgen | 31 | 2018-12-13 | 2024-12-13 |
| Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus nicotinamide - Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus Rash | Phase 2 | Unknown | Second Xiangya Hospital of Central South University | 40 | 2017-08-31 | 2021-02-02 |
| Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) Lanraplenib, Filgotinib, Lanraplenib placebo - Cutaneous Lupus Erythematosus | Phase 2 | Completed | Gilead Sciences | 47 | 2017-05-24 | 2020-06-09 |
| IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus IVIg - Cutaneous Lupus Erythematosus | Early Phase 1 | Completed | University of California, Irvine | 16 | 2013-03-01 | 2015-08-10 |
| Low-dose UVA1 Radiation in Cutaneous Lupus Patients UVA1 radiation treatment - Cutaneous Lupus Erythematosus | Not applicable | Completed | Ben Chong | 6 | 2012-09-01 | 2023-08-25 |
| Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus Cutaneous Lupus educational script - Cutaneous Lupus Erythematosus | Not applicable | Completed | Northwestern University | 31 | 2012-05-01 | 2013-06-03 |
| Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus vitamin D - Cutaneous Lupus Erythematosus | Phase 2 | Terminated | Emory University | 3 | 2011-12-01 | 2013-11-20 |
| A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus PD-0360324, Placebo - Cutaneous Lupus Erythematosus | Phase 1 | Terminated | Pfizer | 28 | 2011-11-01 | 2014-01-29 |
| To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus CC-11050, Placebo - Cutaneous Lupus Erythematosus | Phase 2 | Completed | Amgen | 48 | 2010-10-01 | 2020-06-23 |
| Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE) UV A and B irradiation - Cutaneous Lupus Erythematosus | Not applicable | Completed | Spirig Pharma Ltd. | 20 | 2009-11-01 | 2016-03-09 |
| Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser laser treatment (Candela Vbeam Perfecta™) - Cutaneous Lupus Erythematosus | Phase 2 | Completed | University of Pennsylvania | 10 | 2007-03-01 | 2010-06-25 |
Showing 20 of 23. Sign in to see all of them.
Lupus Erythematosus, Cutaneous (23) · Lupus Erythematosus, Systemic (4) · Lupus Erythematosus, Discoid (3) · Autoimmune Diseases (1) · Dermatomyositis (1) · Polymyositis (1) · Scleroderma, Systemic (1) · Sjogren's Syndrome (1)
Connective Tissue Diseases (23) · Skin Diseases (23) · Skin and Connective Tissue Diseases (23) · Immune System Diseases (4) · Autoimmune Diseases (3) · Arthritis (1) · Arthritis, Rheumatoid (1) · Dry Eye Syndromes (1) · Eye Diseases (1) · Joint Diseases (1) · Lacrimal Apparatus Diseases (1) · Mouth Diseases (1) · Muscular Diseases (1) · Musculoskeletal Diseases (1) · Myositis (1)
Standard of Care (2) · CC-11050 (1) · GLPG0634 (1) · Imiquimod (1) · Immunoglobulins, Intravenous (1) · Niacinamide (1) · Vitamin D (1) · anifrolumab (1) · tapinarof (1)
Amgen (2) · Gilead Sciences (2) · Heinrich-Heine University, Duesseldorf (2) · Northwestern University (2) · AstraZeneca (1) · Ben Chong (1) · Centre for Human Drug Research, Netherlands (1) · EMD Serono Research & Development Institute, Inc. (1) · Emory University (1) · European Society of Cutaneous Lupus Erythematosus e.V. (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Noxopharm Limited (1) · Pfizer (1) · Sanofi (1) · Second Xiangya Hospital of Central South University (1)
United States (14) · Germany (7) · Canada (5) · Spain (5) · Australia (4) · Poland (4) · Bulgaria (3) · China (3) · Italy (3) · United Kingdom (3) · Argentina (2) · Brazil (2) · Chile (2) · Czechia (2) · Mexico (2)
Annegret Kuhn, MD (4) · Benjamin F Chong, MD, MSCS (1) · Laura K DeLong, MD, MPH (1) · Paras Vakharia (1) · Qianjin Lu, MD, PhD (1) · R. Rissmann, RPh, PhD (1) · Roopal Kundu, M.D. (1) · Sergei Grando, MD PhD D.Sc. (1) · Victoria P Werth, M.D. (1) · Xiaohong Han (1)
PMID 26376111, PMID 34498056, PMID 35390178, PMID 41136221
2004 (1), 2018 (1), 2025 (1)